The Debate Over Bevacizumab for Metastatic Breast Cancer
Author Information
Author(s): Sudeep Gupta
Primary Institution: Tata Memorial Hospital
Conclusion
The FDA's decision to remove the metastatic breast cancer indication for bevacizumab is based on a lack of overall survival improvement despite some progression-free survival benefits.
Supporting Evidence
- Bevacizumab was initially approved based on a trial showing improved progression-free survival.
- Subsequent trials did not show improvement in overall survival.
- A meta-analysis confirmed a statistically significant improvement in progression-free survival.
Takeaway
Some doctors are arguing about whether a drug called bevacizumab should be used for breast cancer because it helps patients live longer without the cancer getting worse, but it doesn't help them live longer overall.
Methodology
The discussion is based on the review of randomized trials and meta-analysis of bevacizumab in metastatic breast cancer.
Potential Biases
There are potential biases from both advocates and critics of bevacizumab, influencing the interpretation of its effectiveness.
Limitations
The trials had variability, and the results may be confounded by crossover among patients.
Participant Demographics
The meta-analysis included data on almost 2500 patients with metastatic breast cancer.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website